NCT01051960View on ClinicalTrials.gov

Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

January 31, 2011

Conditions
Systemic SclerosisShortness of BreathPulmonary Hypertension
Interventions
DRUG

Ambrisentan

Ambrisentan 5mg or 10mg once daily

Trial Locations (1)

90095

David Geffen School of Medicine, University of California, Los Angeles, Los Angeles

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

University of California, Los Angeles

OTHER